Apogee Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: APGE · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1974640
| Field | Detail |
|---|---|
| Company | Apogee Therapeutics, Inc. (APGE) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: APGE
TL;DR
APGE filed an 8-K for shareholder vote matters on 6/5.
AI Summary
Apogee Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 5, 2024. The company, incorporated in Delaware, is involved in biological products and is headquartered in Waltham, MA.
Why It Matters
This filing indicates a formal process of seeking shareholder approval for specific corporate actions, which is a standard but important step in corporate governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial or operational risks.
Key Players & Entities
- Apogee Therapeutics, Inc. (company) — Registrant
- June 5, 2024 (date) — Date of earliest event reported
- June 7, 2024 (date) — Date of report
- Waltham, MA (location) — Principal Executive Offices
FAQ
What specific matters were submitted for a vote of security holders?
The filing does not specify the exact matters submitted for a vote, only that such a submission occurred on June 5, 2024.
When was Apogee Therapeutics, Inc. incorporated?
Apogee Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address of Apogee Therapeutics, Inc.?
The principal executive offices are located at 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, 02453.
What is the IRS Employer Identification Number for Apogee Therapeutics, Inc.?
The IRS Employer Identification Number is 93-4958665.
What is the SIC code for Apogee Therapeutics, Inc.?
The Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-07 16:02:58
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share APGE The Nasdaq Global Ma
Filing Documents
- tm2416675d1_8k.htm (8-K) — 35KB
- 0001104659-24-069619.txt ( ) — 209KB
- apge-20240605.xsd (EX-101.SCH) — 3KB
- apge-20240605_lab.xml (EX-101.LAB) — 33KB
- apge-20240605_pre.xml (EX-101.PRE) — 22KB
- tm2416675d1_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On June 5, 2024, Apogee Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 11, 2024, the record date for the Annual Meeting, there were 42,923,291 shares of voting common stock entitled to vote at the meeting. The proposals considered at the Annual Meeting are described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2024. The final voting results are set forth below. Proposal 1: Election of Directors The following Class I director nominees were elected to serve until the 2027 Annual Meeting of Stockholders based upon the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Andrew Gottesdiener, M.D. 33,888,258 6,873,344 805,441 Peter Harwin 33,716,470 7,045,132 805,441 Michael Henderson, M.D. 34,982,626 5,778,976 805,441 Proposal 2: Ratification of Independent Auditor The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 was ratified as follows: Votes For Votes Against Abstentions Broker Non-Votes 41,560,000 2,163 4,880 0 Proposal 3: Approval of Director Option Grant The grant of options to a director to purchase 100,000 shares of the Company's voting common stock was approved as follows: Votes For Votes Against Abstentions Broker Non-Votes 40,430,389 330,671 542 805,441
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apogee Therapeutics, Inc. Date: June 7, 2024 By: /s/ Michael Henderson, M.D. Name: Michael Henderson, M.D. Title: Chief Executive Officer